Teva Pharmaceutical has announced a collaboration with Shanghai Fosun Pharmaceutical (Fosun Pharma) to advance the global development of the anti-programmed cell death protein 1 (PD1)-Interleukin-2 (IL2) ATTENUKINE therapy, TEV-56278.
The collaboration will enhance clinical data generation for the potential treatment, which utilises Teva’s ATTENUKINE technology designed to offer efficacy with low toxicity across various oncology indications.
Go deeper with GlobalData
Teva Global research and development (R&D) executive vice-president and chief medical officer Eric Hughes stated: “This partnership with Fosun Pharma in the development of our internally developed TEV-56278, an anti-PD1-IL2 ATTENUKINE therapy with the potential to treat devastating cancers, is the latest advance to ensuring the acceleration of our pipeline.
“TEV-56278 demonstrates the strength of Teva’s innovative drug development capabilities and how strategic partnerships with companies such as Fosun Pharma play a pivotal role in advancing therapies on behalf of patients.”
Fosun Pharma will have exclusive rights to develop, manufacture and commercialise the therapy in Mainland China, the Hong Kong Special Administrative Region (SAR), Macau SAR, the Taiwan region and selected countries in Southeast Asia.
Teva retains all corresponding rights outside of these territories. The deal provides the company with insights from Fosun Pharma’s regional data that can be leveraged globally.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataFosun Pharma executive president and global R&D centre CEO Xingli WANG stated: “We are pleased to partner with Teva on the development of TEV-56278.
“This collaboration brings together Teva’s expertise in innovative drug development with Fosun Pharma’s strong oncology development experience and commercial capabilities in the China market, creating a powerful synergy to accelerate the delivery of this important therapy to patients globally.”
TEV-56278 has been specifically engineered to target PD-1 + T cells selectively.
This targeted method could significantly improve patient outcomes across multiple oncology diseases.
In February 2025, Teva and Alvotech have announced the US launch of the Selarsdi (ustekinumab-aekn) injection, a biosimilar to Johnson & Johnson’s Stelara (ustekinumab).
